P-241 MP-30: Safety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the respond study
RA Preston, F Sun, L Tarasenko - American Journal of …, 2005 - search.proquest.com
Amlodipine/atorvastatin combination therapy has been demonstrated to be an effective
approach for the management of concomitant hypertension (HTN) and dyslipidemia (DYS) …
approach for the management of concomitant hypertension (HTN) and dyslipidemia (DYS) …
P-413: The efficacy and safety of fixed-dose combinations of amlodipine and atorvastatin in the treatment of patients with concomitant hypertension and dyslipidemia
RA Preston, P Harvey, O Herfert… - American Journal of …, 2004 - search.proquest.com
Hypertension (HTN) and dyslipidemia (DYS) commonly coexist. Patients with concurrent
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial
FH Messerli, GL Bakris, RD Ferrera… - The Journal of …, 2006 - Wiley Online Library
The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …
A randomized, placebo‐controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 …
RA Preston, P Harvey, O Herfert… - The Journal of …, 2007 - Wiley Online Library
Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia
K McKeage, MAA Siddiqui - American journal of cardiovascular drugs, 2008 - Springer
Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single‐pill therapy
MR Cowie - International journal of clinical practice, 2005 - Wiley Online Library
Single‐pill amlodipine besylate/atorvastatin calcium (Caduet®, Pfizer Inc, NY, USA) is the
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …
Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia
CP Lin, TJ Hsu, YC Tung, FC Hsiao… - Journal of the …, 2024 - Am Heart Assoc
Background Hypertension and hypercholesterolemia are important risk factors for
cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is …
cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is …
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease
MP Curran - Drugs, 2010 - Springer
Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
Single‐pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study)
R Blank, J LaSalle, R Reeves, J Maroni… - The journal of …, 2005 - Wiley Online Library
The Gemini Study was a 14‐week, open‐label, noncomparative, office‐based, multicenter
trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and …
trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and …
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
M Devabhaktuni, S Bangalore - Vascular health and risk …, 2009 - Taylor & Francis
Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …
risk factors which together cause an increase in coronary heart disease-related events that …